Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease

The aim was to examine actual health care cost in patients with gastroesophageal reflux disease (GERD) who were initiated on proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB) as first-line therapy in Japanese real-world clinical settings. BACKGROUND: To date, cost-utility eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Miwa, Hiroto, Shiotani, Akiko, Takeda, Masayoshi, Eda, Masahiro, Kato, Toshiaki, Yajima, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983749/
https://www.ncbi.nlm.nih.gov/pubmed/35316226
http://dx.doi.org/10.1097/MCG.0000000000001685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983749/
https://www.ncbi.nlm.nih.gov/pubmed/35316226
http://dx.doi.org/10.1097/MCG.0000000000001685

Ejemplares similares